Article: STUDY REINFORCES CLINICAL EFFICACY OF ALK-ABELLO'S TABLET AGAINST GRASS POLLEN ALLERGY.

(Full text of statement. Contact details below.)

COPENHAGEN, Jan. 6 /PRNewswire-AsiaNet/ --

According to preliminary results from a new study (GT-07) announced today, ALK-Abello's ground-breaking tablet-based allergy immunotherapy treatment reduces rhino-conjunctivitis (hay fever) symptoms by 37%, whilst reducing the need for symptom relieving medication by 41% (compared with placebo).

The GT-07 study demonstrates the efficacy and confirms the favourable safety profile of the grass tablet, recently reported in the phase IIb/III trial (GT-02) -- the largest allergy immunotherapy study ever performed(1).

"These are exciting results for ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!